<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839800</url>
  </required_header>
  <id_info>
    <org_study_id>D589LC00001</org_study_id>
    <nct_id>NCT00839800</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Efficacy of Symbicort® SMART.</brief_title>
  <acronym>SAKURA</acronym>
  <official_title>A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort
      Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler
      160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma
      therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study</measure>
    <time_frame>week 52</time_frame>
    <description>Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Asthma Exacerbations</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF)</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>The mean value from a 52-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEF</measure>
    <time_frame>2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period</time_frame>
    <description>The mean value from a 52-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>4, 12, 24, 36 and 52 weeks after randomization</time_frame>
    <description>The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of As-needed Medication</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights With Awakening(s) Due to Asthma Symptoms</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>The mean value from the treatment period was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-free Days (no Symptoms and no Awakenings)</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of As-needed-free Days</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)</measure>
    <time_frame>52-week treatment period</time_frame>
    <description>An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>4, 12, 24, 36 and 52 weeks after randomization</time_frame>
    <description>The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2091</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler</intervention_name>
    <description>160/4.5 µg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline Turbuhaler</intervention_name>
    <description>0.4 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA)
             2007 with a documented history of at least 6 months duration.

          -  Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to
             baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg
             terbutaline Turbuhaler

          -  Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12
             weeks.

        Exclusion Criteria:

          -  Respiratory infection affecting the asthma, as judged by the investigator, within 4
             weeks.

          -  Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS
             within 12 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tito Atienza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Mediatrix Medical Center, Lipa City, Philippines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monte Grande</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Brasil</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guang Zhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tres Rios</city>
        <state>Cartago</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barrio San Bosco</city>
        <state>San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cegled</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimabatore</city>
        <state>Tamilnadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noida</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komaki</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isesaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ORA</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>AKO</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kokubunji</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Machida</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kubang Kerian</city>
        <state>Kelantan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surco</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naimuang</city>
        <state>Nakhonratchasima</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Costa Rica</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <results_first_submitted>February 21, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2012</results_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Symbicort Turbuhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 16 February 2009, and the last participant completed the study on 23 February 2011. A total of 3209 participants were enrolled at 148 centres in 13 countries in Asia, America and Europe, and 2091 participants who fulfilled the randomisation criteria were randomised.</recruitment_details>
      <pre_assignment_details>The study started with an enrolment visit, Visit 1, 1-7 days prior to Visit 2 (run-in). At Visit 2 patients had to have a reversibility of ≥12% relative to baseline and their pre-bronchodilatory Forced expiratory volume in one second (FEV1) had to be ≥50% of the predicted normal value.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort SMART</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
        </group>
        <group group_id="P2">
          <title>Symbicort+Terbutaline As Needed</title>
          <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1049"/>
                <participants group_id="P2" count="1042"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="956"/>
                <participants group_id="P2" count="932"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Enrolment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-Specific Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe Non-Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort SMART</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
        </group>
        <group group_id="B2">
          <title>Symbicort+Terbutaline As Needed</title>
          <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1049"/>
            <count group_id="B2" value="1042"/>
            <count group_id="B3" value="2091"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" lower_limit="16" upper_limit="84"/>
                    <measurement group_id="B2" value="45.6" lower_limit="16" upper_limit="85"/>
                    <measurement group_id="B3" value="45.7" lower_limit="16" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="692"/>
                    <measurement group_id="B3" value="1414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="350"/>
                    <measurement group_id="B3" value="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study</title>
        <description>Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.</description>
        <time_frame>week 52</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study</title>
          <description>Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="1042"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asthma Exacerbations</title>
        <description>Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asthma Exacerbations</title>
          <description>Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>Asthma exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="1042"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (PEF)</title>
        <description>The mean value from a 52-week treatment period.</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF)</title>
          <description>The mean value from a 52-week treatment period.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>Liter/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1034"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.8" spread="102.2"/>
                    <measurement group_id="O2" value="324.7" spread="101.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEF</title>
        <description>The mean value from a 52-week treatment period.</description>
        <time_frame>2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEF</title>
          <description>The mean value from a 52-week treatment period.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1034"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.2" spread="102.6"/>
                    <measurement group_id="O2" value="327.8" spread="103.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.</description>
        <time_frame>4, 12, 24, 36 and 52 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>Liter (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="1042"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.258" spread="0.76"/>
                    <measurement group_id="O2" value="2.222" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of As-needed Medication</title>
        <description>The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Use of As-needed Medication</title>
          <description>The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>inhalations/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1032"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.39"/>
                    <measurement group_id="O2" value="1.46" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score</title>
        <description>The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score</title>
          <description>The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1034"/>
                <count group_id="O2" value="1025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.04"/>
                    <measurement group_id="O2" value="1.22" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nights With Awakening(s) Due to Asthma Symptoms</title>
        <description>The mean value from the treatment period was presented here.</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Nights With Awakening(s) Due to Asthma Symptoms</title>
          <description>The mean value from the treatment period was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>Nights With Awakening(s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1024"/>
                <count group_id="O2" value="1025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="27.1"/>
                    <measurement group_id="O2" value="17.5" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations</title>
        <description>Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations</title>
          <description>Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="1042"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom-free Days (no Symptoms and no Awakenings)</title>
        <description>A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom-free Days (no Symptoms and no Awakenings)</title>
          <description>A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>symptom-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1034"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="37.8"/>
                    <measurement group_id="O2" value="41.6" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of As-needed-free Days</title>
        <description>An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of As-needed-free Days</title>
          <description>An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>percentage of as-needed-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1032"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="36.7"/>
                    <measurement group_id="O2" value="47.2" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)</title>
        <description>An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.</description>
        <time_frame>52-week treatment period</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)</title>
          <description>An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>percentage of asthma-control days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1033"/>
                <count group_id="O2" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="37.3"/>
                    <measurement group_id="O2" value="37.9" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ)</title>
        <description>The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.</description>
        <time_frame>4, 12, 24, 36 and 52 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort SMART</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
          </group>
          <group group_id="O2">
            <title>Symbicort+Terbutaline As Needed</title>
            <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ)</title>
          <description>The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.</description>
          <population>The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1040"/>
                <count group_id="O2" value="1038"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.162" spread="0.78"/>
                    <measurement group_id="O2" value="1.289" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort SMART</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed</description>
        </group>
        <group group_id="E2">
          <title>Symbicort+Terbutaline As Needed</title>
          <description>Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cleft Lip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Gastric Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>H1n1 Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Sternal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Breast Cancer In Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Intestinal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Abortion Threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Premature Baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Infertility Male</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1042"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1042"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

